Galvus Won’t Proceed In U.S. Without More FDA Clarity On Prospects, Novartis Says
This article was originally published in The Pink Sheet Daily
Executive Summary
DPP-4 inhibitor’s NDA is on hold in U.S. while firm pursues European launch; Novartis balks at FDA request for large safety study.
You may also be interested in...
Novartis Boosted By Alcon, Generic Sales And Gilenya Launch in Second Quarter
Novartis lifted by strong sales of recently launched products in the second quarter, and by strong growth in its Alcon, generics and consumer health divisions.
Novartis Boosted By Alcon, Generic Sales And Gilenya Launch in Second Quarter
Novartis lifted by strong sales of recently launched products in the second quarter, and by strong growth in its Alcon, generics and consumer health divisions.
Novartis Looks To Recent Launches To Bolster Diovan Against Generic Onslaught
The Swiss pharma predicts hypertension blockbuster still will earn $2 billion annually outside the U.S. after patent expirations.